Magnetic nanocrystals used to carry tumor-killing drugs

Imagine using a focused magnetic field to concentrate anticancer drugs in and around tumors, and then turning off the magnetic field so that the drugs then leave the body.

That possiblity may become a reality as a result of work showing that magnetic nanocrystalline iron-nickel alloys can effectively carry and release anticancer agents. The results of these experiments appear in the journal Acta Biomaterialia.

Devesh Misra, Ph.D., and colleagues at the University of Louisiana at Lafayette first prepared magnetic nickel ferrite (NiFe2O4) nanocrystals coated with the biocompatible polymer polymethacrylic acid (PMAA) and developed methods of hooking the anticancer agent doxorubicin to the ends of the PMAA chains. Characterization experiments showed that the modified nanocrystals retained their strong magnetic properties. The polymer coating prevents the nanocrystals from clumping together, which would degrade their magnetic properties. Moreover, the polymer coating prevents blood proteins from accumulating on the nanocrystals, thereby reducing clearance of the nanocrystals by the immune system.

Drug delivery experiments demonstrated that the nanocrystals slowly and steadily released doxorubicin over 200 hours. However, when the investigators applied a magnetic field to the nanocrystals, drug release rates increased dramatically, with the particles releasing 2.5 times more drug in the first two hours and over the next 24 hours. After 60 hours in a magnetic field, the nanocrystals released approximately 75 percent of their drug payload.

This work is detailed in a paper titled, “On the suitability of nanocrystalline ferrites as a magnetic carrier for drug delivery: functionalization, conjugation and drug release kinetics.” An abstract of this paper is available through PubMed. View abstract.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study unveils why glioblastoma becomes resistant to treatment